EARLY DIFFERENTIAL DIAGNOSTICS AND PROLONGED IMMUNOMODULATORY THERAPY OF CHRONIC INFLAMMATORY DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTS
Abstract
Key words: children, inflammatory demyelinating diseases, diagnostics, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(6):139-145)
About the Authors
O.V. BykovaRussian Federation
A.N. Platonova
Russian Federation
N.V. Gol'tsova
Russian Federation
G.V. Kuznetsova
Russian Federation
L.M. Kuzenkova
Russian Federation
A.N. Boiko
Russian Federation
References
1. Barkhof F., Polman C., Radue E.W. et al. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): magnetic resonance imaging outcomes. 21-th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Greece. 2005. P. 583.
2. Dale R.C., de Sousa C., Chong W.K. et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123 (12): 2407–2422.
3. Hahn C.D., Shroff M.M., Blaser S.I., Banwell B.L. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology. 2004; 62: 806–808.
4. Hynson J.L., Kornberg A.J., Coleman L.T. et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001; 56: 1308–1312.
5. Idrissova Z., Boldyreva M.N., Dekonenko E.P. et al. Acute disseminated encephalomyelitis in children: clinical features and HLA–DR linkage. Eur. J. Neurol. 2003; 10: 537–546.
6. Jacobs L.D., Beck R.W., Simon J.H. et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000; 343: 898–904.
7. Krupp L., Pohl D., Rostasy K. et al. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004; 63: 1966–1967.
8. Krupp Lauren B., Banwell B., Tenembaum S., for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68: 7–12.
9. Marchioni E., Ravaglia S., Piccolo G. et al. Postinfectious inflammatory disorders: subgroups based on prospective follow up. Neurology. 2005; 65: 1057–1065.
10. McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001; 50: 121–127.
11. Mikaeloff Y., Adamsbaum C., Husson B. et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004; 127: 1942–1947.
12. Mikaeloff Y., Suissa S., Vallee L. et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 2004; 144: 246–252.
13. Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59: 1496–1506.
14. Pittock S.J., Wingerchuk D.M., Krecke K. et al. Brain abnormalities in patients with neuromyelitis optica (NMO). Neurology. 2005; 64: 39.
15. Pohl D., Waubant E., Banwell B. et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007; 68 (2): 54–65.
16. Poser C.M., Paty D.W., Scheinberg L. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983; 13: 227–231.
17. Ruggieri M., Iannetti P., Polizzi A. et al. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 2004; 25 (4): 326–335.
18. Schumacker G.A., Beebe G., Kibler R.F. et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N.Y. Acad. Sci. 1965; 122: 552–568.
19. Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002; 59: 1224–1231.
20. Wingerchuk D.M., Pittock S.J., Lennon V.A. et al. Neuromyelitis optica diagnostic criteria revisited: Validation and incorporation of the NMO–IgG serum autoantibody. Neurology. 2005; 64: 38.
21. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica - Clinical predictors of a relapsing course and survival. Neurology. 2003; 60: 848–853.
22. Wingerchuk D.M. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv. Neurol. 2006; 98: 303–318.
Review
For citations:
Bykova O., Platonova A., Gol'tsova N., Kuznetsova G., Kuzenkova L., Boiko A. EARLY DIFFERENTIAL DIAGNOSTICS AND PROLONGED IMMUNOMODULATORY THERAPY OF CHRONIC INFLAMMATORY DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTS. Current Pediatrics. 2009;8(6):139-145.
Email this article 
